| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| No More Fish or Fruit: Intrexon Turns SynBio Focus to Human Health | Frank Vinluan | 01/02/20 | National |
| Bio Roundup: Zolgensma Fallout, Duchenne Redux, Ebola Boost & More | Alex Lash | 08/16/19 | National |
| Bio Roundup: Opioid Exposé, Gilead’s Gambit, Life Science IPOs & More | Frank Vinluan | 07/19/19 | National |
| Kronos Bio Reels In $105M for Drugs That Hit “Undruggable” Targets | Frank Vinluan | 07/18/19 | San Francisco |
| Ideaya and Bicycle Therapeutics IPOs Raise $110M for Cancer Drug R&D | Frank Vinluan | 05/23/19 | San Francisco |
| No Details, But AstraZeneca Touts PARP Drug Win in Pancreatic Cancer | Ben Fidler | 02/26/19 | New York |
| TCR²’s IPO Raises $75M to Bring Cancer Cell Therapy to Solid Tumors | Frank Vinluan | 02/14/19 | Boston |
| Harpoon’s IPO Spears $76M as Prostate Cancer Drug Continues Testing | Frank Vinluan | 02/07/19 | San Francisco |
| OncoMed’s Saga Ends in Reverse Merger with UK-Based Mereo BioPharma | Frank Vinluan | 12/05/18 | San Francisco |
| FDA Puts Mersana Cancer Study on Partial Hold After Patient Death | Frank Vinluan | 07/19/18 | Boston |
| Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On | Ben Fidler | 06/29/18 | National |
| Aravive Seeks Nasdaq Perch Via Reverse Merger With Biotech Versartis | Angela Shah | 06/04/18 | Texas |
| Power to the Patient: Meet Xconomy’s Patient Partnership Award Finalists | Corie Lok | 08/28/17 | Boston |
| Bio Roundup: Frazier v. Trump, Data Dumps, New York Steps & More | Ben Fidler | 08/18/17 | National |
| Houston Biotech Oncolix Announces Reverse Merger, Goes Public | Angela Shah | 08/07/17 | Texas |
| Tesaro Cashes In Again on PARP Blocker With $100M Takeda Deal | Frank Vinluan | 07/27/17 | Boston |
| Endocyte Cuts Workforce by 40 Percent After Clinical Trial Falters | Frank Vinluan | 06/02/17 | Indiana |
| Mersana Plans IPO to Finance Clinical Trials for Breast Cancer Drug | Frank Vinluan | 06/02/17 | Boston |
| Bio Roundup: New Drug Bonanza, Vertex’s Triple Play, CAR-T Race & More | Ben Fidler | 03/31/17 | National |
| Tesaro’s Ovarian Cancer Drug Gets FDA Nod, No Diagnostic Needed | Frank Vinluan | 03/27/17 | Boston |
| Another Notch For “PARP” Blockers As FDA Approves Clovis Cancer Drug | Ben Fidler | 12/19/16 | Boulder/Denver |
| Safety Issue Triggers Partial FDA Hold for Aduro Bio | Ben Fidler | 10/24/16 | San Francisco |
| Guardant Health Maps Cautious Plans For Blood-Based Cancer Screening | Alex Lash | 06/03/16 | San Francisco |
| Tour of Texas: Cancer Moonshot, Lumos, Robyn Metcalfe, & Esperance | Angela Shah | 04/07/16 | Texas |
| Houston Biotech Esperance Eyes $40M Raise to Fund Cancer Drug Push | Angela Shah | 03/30/16 | Texas |
| Big Deals in Texas (ZS Pharma, HomeAway, Gravitant) & Other News | Angela Shah | 11/09/15 | Texas |
| East Coast Biotech Roundup: Biogen, Epizyme, Armored CARS, & More | David Holley | 07/13/15 | Boston |
| After Celgene Deal, Juno Revs Armored CAR For Ovarian Cancer Trial | Alex Lash | 07/10/15 | Seattle |
| Array and Novartis End Development Deal for Cancer Drug Binimetinib | Michael Davidson | 12/04/14 | Boulder/Denver |
